TGF-β: Transforming growth factor-beta Treg: Regulatory T cell DC: Dendritic cells TMB: Tumor mutational burden TILs: Tumor-infiltrating lymphocytes ICD: Immunogenic cell death RIPF: Radiation-induced pulmonary fibrosis MoDCs: Monocyte-derived DCs GM-CSF: Granulocyte–macrophage colony-st...
Therapies using TGF-尾 inhibitors and/or PD-1 inhibitors are disclosed. These drugs at certain doses (including flat dosing) and regimens can be used to treat or prevent proliferative diseases such as solid tumors, including pancreatic cancers. Further combination and uses thereof are also ...
BetaPowered by GenAIQuestions answered in this article Keywords 1. Introduction 2. Intermediate EMT (partial EMT) states in carcinoma progression 3. TGF-β as a driver of EMT 4. The role of TGF-β in immune evasion 5. TGF-β controls cell cycle arrest associated with the acquisition of che...
Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Reversal of TGF-β -induced immunosuppression is a new and promising approach to cancer therapy, with potential applications in other diseases such as AIDS... Slawomir Wojtowicz-Praga - 《Investigational New Drugs》 被引量: 765发表...
et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J. Clin. Invest. 101, 890–898 (1998). CAS PubMed PubMed Central Google Scholar Voll, R. E. et al. ...
et al. The immunosuppressive factors IL-10, TGF-beta, and VEGF do not affect the antigen-presenting function of CD40-activated B cells. J. Exp. Clin. Cancer Res. 31, 47 (2012). CAS PubMed PubMed Central Google Scholar Kondo, E. et al. CD40-activated B cells can be generated in ...
TGF-β: Transforming growth factor β TNF-α: Tumor necrosis factor α uPA: Urokinase plasminogen activator uPAR: Urokinase plasminogen activator receptor VCAM-1: Vascular cell adhesion molecule-1 VEGF: Vascular endothelial growth factor ...
Over a dozen small molecules inhibit the kinase activity of TGF-beta receptors. Several commonly used drugs appear to have unanticipated anti-TGF-beta activity and may therefore have a role in antifibrotic therapy. Because TGF-beta has important physiological functions, inhibiting its activity might ...
Hypercholesterolemia is a major risk factor in atherosclerosis development and lipid-lowering drugs (i.e., statins) remain the treatment of choice. Despite effective reduction of LDL cholesterol in patients, a residual cardiovascular risk persists in some individuals, highlighting the need for further ...
transforming growth factor-beta (TGF-β)41, VEGF42, insulin-like growth factor 1 (IGF1)40, hepatocyte growth factor (HGF)43, tumor necrosis factor-alpha (TNF-α)44, Fms-like tyrosine kinase 3 (FLT3)45, and so on. These cytokines function upstream of RTKs and regulate multiple downstream...